Neuroinflammatory and Oxidative Stress Pathway Targets

The term **"Neuroinflammatory and Oxidative Stress Pathway Targets"** encompasses a variety of molecular components and signaling pathways that collectively mediate neuroinflammation and oxidative damage in the nervous system. It does not represent a single molecule, receptor, or defined structural entity. Instead, it refers to a functional group of targets implicated in the initiation, modulation, and progression of neuroinflammation (primarily driven by cells like microglia and astrocytes via cytokines such as TNF-α, IL-1β, IL-6) as well as oxidative stress (mediated by enzymes like NADPH oxidases, mitochondrial dysfunction, or impaired antioxidant response via the Nrf2 pathway)[1][2][3][4][7]. These overlapping and interconnected pathways are central to the pathogenesis of neurodegenerative diseases (e.g., Alzheimer’s disease, Parkinson’s disease, multiple sclerosis, ALS) and are targets for diverse drug development efforts, including anti-inflammatory drugs, antioxidants, immune modulators, and pathway-specific agents[1][2][3][4][5][7]. **Summary of issues:** - "Neuroinflammatory and Oxidative Stress Pathway Targets" is *not* a canonical target—it is a descriptive/umbrella term. - There are no unified aliases or abbreviations; it broadly covers multiple molecular classes (receptors, enzymes, transcription factors, cytokines). - It cannot be assigned a clear canonical name under standard molecular target nomenclature. - For structured information extraction, each *actual* molecular target within these pathways (e.g., "Nuclear factor erythroid 2-related factor 2 (Nrf2)", "Nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB)", "G-protein coupled receptor 55 (GPR55)", "Cyclooxygenase-2 (COX-2)") should be characterized individually[1][2][5][6][7].

Activation or inhibition of transcription factors (e.g., Nrf2 activation for antioxidant response, NF-κB inhibition for anti-inflammatory effects)[1][2] Inhibition of pro-inflammatory cytokines or their receptors (e.g., anti-TNF-α therapies, COX inhibition by NSAIDs)[4] Suppression of oxidative stress (e.g., by boosting glutathione pathways or scavenging reactive oxygen species)[3][4][7] Modulation of microglial activation[7][3] Interference with specific G-protein-coupled receptor signaling (e.g., GPR55 modulation)[5]